NCR201
/ Nuwacell Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 02, 2025
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Nuwacell Biotechnologies Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease
May 19, 2025
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Nuwacell Biotechnologies Co., Ltd.
New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
1 to 2
Of
2
Go to page
1